Work

Antiviral In Vitro Screening Using SARS-CoV-2 and MERS-CoV - Cytotoxicity of Drugs v1

Year: 2025

Type: preprint

Abstract: The protocol evaluates compounds to determine their antiviral activity against coronaviruses. The antiviral activity is evaluated based on the 50% inhibitory concentration (IC50) and the 50% effective concentration (EC50). Two cell lines can be used for these assays (A549+ACE2+TMP (Invivogen) or VeroE6/TMPRSS2 cells (XenoTech)). The multiplicity of infection (MOI) will depend on the virus stock titer. The incubation time can vary if using a reporter virus. The assay can be performed in 96-well plates (medium throughput screening) or 384-well plates (high throughput screening).

DOI: 10.17504/protocols.io.5qpvooxzzv4o/v1

Authors: Nadine Alvarez, Sean Fitzgerald, Fatima Ijaz

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Funders: National Institutes of Health, National Institute of Allergy and Infectious Diseases

Awards: G3762391733, G9000344158

OpenAlex ID: W4412869755

Cites:

Cited by:

Related to: 10